Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12127887 | 0.95 | DRD2 (0.48) | DRD2SLC6A4GSK3BSCN9ASCN5A | |
| SCHEMBL9764630 | 0.88 | DRD2 (0.53) | DRD2SLC6A4GSK3BRORC | |
| SCHEMBL21088053 | 0.87 | APP (0.50) | DRD2SLC6A4GSK3BTUBB4ATUBB | |
| SCHEMBL15712564 | 0.79 | DRD2 (0.50) | DRD2SLC6A4SCN9ASCN5ARORC | |
| SCHEMBL17060397 | 0.78 | DRD2 (0.49) | DRD2SLC6A4SCN9ASCN5ARORC | |
| SCHEMBL17060402 | 0.77 | DRD2 (0.48) | DRD2SLC6A4SCN9ASCN5ARORC | |
| SCHEMBL28127883 | 0.77 | ALDH1A1 (0.49) | DRD2SLC6A4SCN9ASCN5AKMT2A | |
| SCHEMBL21089013 | 0.76 | APP (0.55) | DRD2SLC6A4SCN9ASCN5AAPP | |
| SCHEMBL29104115 | 0.76 | GSK3B (0.43) | DRD2SLC6A4GSK3BSCN9ASCN5A | |
| SCHEMBL21088199 | 0.76 | SLC6A4 (0.40) | DRD2SLC6A4GSK3BTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| CN-106414429-A | Pyrazole compounds and their use as T-type calcium channel blockers | 埃科特莱茵药品有限公司 | 2017-02-15 | — | — | CN | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | DRD2 913/4885SLC6A4 989/4885GSK3B 2840/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | DRD2 913/4885SLC6A4 989/4885GSK3B 2840/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | DRD2 913/4885SLC6A4 989/4885GSK3B 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.